Results 81 to 90 of about 16,718 (212)

Novel Treatments from Inhibition of the Intestinal Sodium–Hydrogen Exchanger 3

International Journal of Nephrology and Renovascular Disease, 2021
Csaba P Kovesdy,1 Adebowale Adebiyi,2 David Rosenbaum,3 Jeffrey W Jacobs,3 L Darryl Quarles1 1Division of Nephrology, University of Tennessee Health Science Center, Memphis, TN, USA; 2Department of Physiology, University of Tennessee Health Science ...
Kovesdy CP, Adebiyi A, Rosenbaum D, Jacobs JW, Quarles LD   +4 more
doaj  

Hyperphosphatemia Contributes to Skeletal Muscle Atrophy in Mice

Chronic kidney disease (CKD) is associated with various pathologic changes, including elevations in serum phosphate levels (hyperphosphatemia), vascular calcification, and skeletal muscle atrophy.
Abul Fajol, Svetlana Komarova, Matthew S. Alexander, Brian Czaya, Jordan Bradley, Glenn C. Rowe, Christian Faul, Seth Bollenbecker, Kylie Heitman, Sarah Madison Thomas, Qing Li, Stefanie Krick   +11 more
core   +1 more source

Efficacy of a Once-Daily Supplement in Managing Canine Chronic Kidney Disease

Animals
Background: Chronic kidney disease (CKD) in companion animals leads to progressive renal deterioration and metabolic complications such as hyperphosphatemia and metabolic acidosis, particularly in advanced stages.
Francesca Perondi, Alessio Ruggiero, Monica Isabella Cutrignelli, Ilaria Lippi, Giorgia Meineri, Elisa Martello   +5 more
doaj   +1 more source

The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease [PDF]

Терапевтический архив, 2016
Aim. To study whether the excessive production of serum fibroblast growth factor 23 (FGF-23) may be reduced with phosphate-binding agents to treat hyperphosphatemia in patients with Stage VD chronic kidney disease (CKD). Subjects and methods.
N A Mukhin, Yu S Milovanov, L V Kozlovskaya, I A Dobrosmyslov, L Yu Milovanova   +4 more
doaj  

Diabetes Mellitus and Younger Age Are Risk Factors for Hyperphosphatemia in Peritoneal Dialysis Patients

, 2017
Hyperphosphatemia has been associated with adverse outcomes in patients with end stage kidney disease (ESKD). The purpose of this study was to determine risk factors for hyperphosphatemia in ESKD patients treated with peritoneal dialysis (PD).
Brendan McCormick, Swapnil Hiremath, Deborah Zimmerman, Hawken, Steven, Leung, Simon, Hiremath, Swapnil, Imtiaz, Rameez, Rameez Imtiaz, Steven Hawken, Simon Leung, Zimmerman, Deborah L., McCormick, Brendan B.   +11 more
core   +1 more source

Hyperphosphatemia among patients with chronic kidney disease

, 2015
Background: Hyperphosphatemia alone or in combination with hypercalcemia has been associated with increased mortality and morbidity among patients with chronic kidney disease (CKD).
Alizadeh-Atar, Gh.R., Chitsazian, Z., Beladi-Mousavi, S.S., Hayati, F., Shayanpour, Sh.   +4 more
core  

Risk factor analysis and prediction model construction for hyperphosphatemia in uremic patients after dialysis treatment

Linchuang shenzangbing zazhi
ObjectiveTo identify the independent risk factors for hyperphosphatemia in uremic patients after dialysis and to develop a predictive model to guide clinical intervention.MethodsA retrospective analysis was conducted on the clinical data of 155 uremic ...
Zhang Bin-chuan, Liu Kun, Wang Cheng-jun, Zhang Song-tao, Zhu Guan-neng   +4 more
doaj  

Phosphate-Trapping Liposomes for Long-Term Management of Hyperphosphatemia

, 2022
Hyperphosphatemia is a typical complication of end-stage renal disease, characterized by elevated and life-threatening serum phosphate levels. Hemodialysis does not enable sufficient clearance of phosphate, due to slow cell-to-plasma kinetics of ...
Tamar Sadan, Sadan, Tamar, Menachem Motiei, Tzror-Azankot, Chen, Anaki, Adi, Popovtzer, Rachela, Rachela Popovtzer, Chen Tzror-Azankot, Motiei, Menachem, Adi Anaki   +9 more
core   +1 more source

Gigantic hip mass as the initial presentation of hyperphosphatemic familial tumoral calcinosis [PDF]

Archive of Oncology
Introduction: Hyperphosphatemic familial tumoural calcinosis (HFTC) is a rare autosomal recessive disorder characterised by ectopic calcium phosphate deposition around the joints due to mutations affecting phosphate regulation.
Krishnan Surya, Murali Anjali, Keechilat Pavithran   +2 more
doaj   +1 more source

Role of hyperphosphatemia on cardiovascular disease in dialysis patients

, 2006
The first cause of mortality in the dialysis population is cardiovascular disease. Accelerated atherosclerosis and vascular calcifications play a key role in the pathogenesis of cardiovascular disease in chronic kidney disease (CKD) patients.
Brancaccio, Diego, Gallieni, Maurizio, Cozzolino, Mario   +2 more
core   +1 more source